GlassScriptPhysician profile
Hoa T Tran
NPI 1912088089
$2,297.12
in general payments reported to CMS, 2019-2025
24 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $348 · 2022: $321 · 2023: $481 · 2024: $703 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $379.83 | 2021-2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.54 | 2021-2025 | Ofev |
| Genzyme Corporation | $268.83 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $166.59 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $165.08 | 2021-2025 | Dupixent |
| Electromed, INC. | $134.44 | 2024-2025 | Smartvest |
| Harmony Biosciences LLC | $121.29 | 2024-2025 | |
| Glaxosmithkline, LLC. | $115.27 | 2021-2025 | Nucala |
| United Therapeutics Corporation | $110.96 | 2021-2025 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $99.19 | 2021-2023 | Breztri |
| Grifols USA, LLC | $97.13 | 2021-2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $41.93 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $39.93 | 2021 | |
| Pulmonx Corporation | $35.35 | 2023-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Mallinckrodt Hospital Products INC. | $35.04 | 2023 | Acthar |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.15 | 2021-2022 | |
| Insmed, INC. | $33.08 | 2025 | Arikayce, Brinsupri |
| Lilly USA, LLC | $20.88 | 2025 | Zepbound |
| Baxter Healthcare | $18.79 | 2022 | |
| Axsome Therapeutics, INC. | $18.02 | 2023 | Sunosi |
| Mylan Specialty L.P. | $16.22 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $15.37 | 2021 | |
| Advanced Respiratory, INC | $14.44 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hoa Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.